Singapore’s TauRx Chief Says Alzheimer’s Disease Candidate May Enter Phase III Trials Soon
This article was originally published in PharmAsia News
Executive Summary
Phase III testing is gathering pace on novel drugs targeting tau buildup, the head of Singapore-based TauRx says, adding that the company has enough cash on hand to complete a Phase III study for an Alzheimer’s treatment that has eluded major drug companies focused on amyloids.